Biomarkers can significantly influence treatment decisions by identifying patients who are more likely to benefit from specific targeted therapies or immunotherapies. For instance, a patient with a HER2-positive breast cancer may be treated with HER2 inhibitors like trastuzumab, while a patient with an EGFR mutation in lung cancer may receive EGFR inhibitors.
